Chicago Capital LLC Boosts Stock Position in Insulet Co. (NASDAQ:PODD)

Chicago Capital LLC boosted its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 30.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 105,610 shares of the medical instruments supplier's stock after purchasing an additional 24,747 shares during the quarter. Chicago Capital LLC owned about 0.15% of Insulet worth $22,915,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Insulet by 5.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 3,365 shares of the medical instruments supplier's stock valued at $896,000 after buying an additional 187 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of Insulet in the first quarter valued at $1,140,000. Synovus Financial Corp lifted its stake in shares of Insulet by 12.4% in the first quarter. Synovus Financial Corp now owns 3,716 shares of the medical instruments supplier's stock valued at $989,000 after buying an additional 410 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Insulet by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 96,390 shares of the medical instruments supplier's stock valued at $25,676,000 after buying an additional 1,232 shares in the last quarter. Finally, Vontobel Holding Ltd. lifted its stake in shares of Insulet by 91.0% in the first quarter. Vontobel Holding Ltd. now owns 3,888 shares of the medical instruments supplier's stock valued at $1,026,000 after buying an additional 1,852 shares in the last quarter.

Insider Transactions at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the business's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the sale, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.80% of the company's stock.

Insulet Price Performance

Insulet stock traded down $4.05 during mid-day trading on Tuesday, hitting $164.05. 735,505 shares of the company traded hands, compared to its average volume of 909,518. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The stock has a market cap of $11.47 billion, a price-to-earnings ratio of 56.37, a price-to-earnings-growth ratio of 3.09 and a beta of 0.98. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The stock has a fifty day moving average price of $180.59 and a 200-day moving average price of $178.27.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business's quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 EPS. On average, equities analysts predict that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PODD. Robert W. Baird raised shares of Insulet from a "neutral" rating to an "outperform" rating and raised their price target for the company from $180.00 to $238.00 in a research report on Thursday, December 21st. Barclays lowered their price objective on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating on the stock in a research report on Monday, February 26th. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $190.00 to $225.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. Piper Sandler reduced their target price on shares of Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a research note on Friday, February 23rd. Finally, Stifel Nicolaus lifted their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a "hold" rating in a research note on Monday, February 5th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and an average target price of $250.33.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.